Case Report: Chronic myeloid leukemia in a 13-year-old—a rare pediatric case of extreme hyperleukocytosis in chronic phase

/L). The diagnosis was made by peripheral smear and bone marrow biopsy, showing Chronic Phase CML with less than 3% blasts along with intense granulocytic hyperplasia. Molecular studies by PCR identified the BCR:ABL1 fusion transcript. The initial treatment approach emphasized cytoreduction therapy with hydroxyurea, intravenous fluid administration, and preventive medication with allopurinol to protect against the risk of tumor lysis syndrome. After the patient became stabilized, imatinib, a first-line tyrosine kinase inhibitor, was started. The supportive care consisted of transfusion support and gastrointestinal protection. The patient responded quite well to therapy and was therefore discharged with instructions for further follow-up care. As highlighted by this case, the importance of prompt diagnosis, the initiation of cytoreduction therapy, and the use of molecular therapy in treating CML in children cannot be neglected. CML in children is an uncommon but curable form of leukemia.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-04-01
DOI
https://doi.org/10.3389/fmed.2026.1809227
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Case Report: Chronic myeloid leukemia in a 13-year-old—a rare pediatric case of extreme hyperleukocytosis in chronic phase

Johnny Amer, Mohammad Y. Asees, Toleen Abdalhaq
Frontiers in Medicine
Chronic Myeloid Leukemia Treatments
article

Case Report: Chronic myeloid leukemia in a 13-year-old—a rare pediatric case of extreme hyperleukocytosis in chronic phase

Johnny Amer, Mohammad Y. Asees, Toleen Abdalhaq
article en

Abstract

/L). The diagnosis was made by peripheral smear and bone marrow biopsy, showing Chronic Phase CML with less than 3% blasts along with intense granulocytic hyperplasia. Molecular studies by PCR identified the BCR:ABL1 fusion transcript. The initial treatment approach emphasized cytoreduction therapy with hydroxyurea, intravenous fluid administration, and preventive medication with allopurinol to protect against the risk of tumor lysis syndrome. After the patient became stabilized, imatinib, a first-line tyrosine kinase inhibitor, was started. The supportive care consisted of transfusion support and gastrointestinal protection. The patient responded quite well to therapy and was therefore discharged with instructions for further follow-up care. As highlighted by this case, the importance of prompt diagnosis, the initiation of cytoreduction therapy, and the use of molecular therapy in treating CML in children cannot be neglected. CML in children is an uncommon but curable form of leukemia.

Frontiers in MedicineVol. 13
An-Najah National University (PS)
Good health and well-being
Openalex Percentile: Top 32%
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Case Report: Chronic myeloid leukemia in a 13-year-old—a rare pediatric case of extreme hyperleukocytosis in chronic phase — Johnny Amer, Mohammad Y. Asees, et al. · Frontiers in Medicine (2026) | TGRS Research Map | TGRS